One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
Zepbound is the “superior” choice for people looking to shed a few pounds, at least compared to Novo Nordisk’s (NVO) Wegovy, ...
Shares of Eli Lilly & Co. LLY advanced 1.69% to $813.33 Tuesday, on what proved to be an all-around mixed trading session for ...
Parts of New York state faced up to five feet of snow over the last few days and more is coming across the Great Lakes region ...
Pharma vs pushes back as Senators look into telehealth moves, startups using AI for small molecule drugs, and more.
Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback